A Phase 1 interventional study of tiotropium in Healthy, sponsored by Solventum US LLC. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-02.
Sponsored by Solventum US LLC · Phase 1, Interventional, and Basic science
The purpose of this study is to compare the absorption of two different inhalation products with the reference product in healthy volunteers.
Healthy subjects will be enrolled and will receive single doses of 2 test inhalation products and one reference inhalation product according to a three-period cross-over design. Subjects will use the patient instruction leaflet to understand how each inhaler is administered. Plasma tiotropium levels will be measured pre-dose and over 8 hours post-dose.
Solventum US LLC is the lead sponsor of 62 studies on the registry; 2 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
tiotropium
Drug: tiotropium
tiotropium
Drug: tiotropium
tiotropium
Drug: tiotropium
four inhalations
Also known as: Spiriva Respimat
peak plasma concentration
measured by noncompartmental analysis
Time frame: 8 hours
adverse events
reported adverse events
Time frame: 8 hours
area under the plasma concentration vs. time curve
measured by the trapezoidal rule
Time frame: 8 hours
Plan to share: Yes — will share summary data
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Solventum US LLC